Stanford professor Russ Altman emphasizes that AI is opening new opportunities to understand how medicines interact with specific proteins, and build more highly customized therapies. He points to DeepMind’s AlphaFold 2 deep learning system as a particularly powerful new tool for re-envisioning how drugs are discovered and designed.
Related
Luke Sykora,
Stanford University
Starting Up in a Downturn
An Entrepreneurial Thought Leaders mini-guide for aspiring founders facing a troubled economy.
Josh Makower, MD,
Stanford Byers Center for Biodesign
The Biodesign Innovation Process [Entire Talk]
Innovation isn’t random – it’s a process that can be learned, improved, and effectively deployed to solve specific problems.
Josh Makower, MD,
Stanford Byers Center for Biodesign
The Biodesign Innovation Process [Entire Talk]
Innovation isn’t random – it’s a process that can be learned, improved, and effectively deployed to solve specific problems.
John Felts,
Cruz Foam
Engineering Green Materials [Entire Talk]
To scale a technology, engineers need to think beyond the technology itself.
John Felts,
Cruz Foam
Engineering Green Materials [Entire Talk]
To scale a technology, engineers need to think beyond the technology itself.
